GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precision BioSciences Inc (NAS:DTIL) » Definitions » Beneish M-Score

Precision BioSciences (Precision BioSciences) Beneish M-Score : 6.55 (As of Apr. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Precision BioSciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 6.55 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Precision BioSciences's Beneish M-Score or its related term are showing as below:

DTIL' s Beneish M-Score Range Over the Past 10 Years
Min: -2.07   Med: 1.05   Max: 6.55
Current: 6.55

During the past 7 years, the highest Beneish M-Score of Precision BioSciences was 6.55. The lowest was -2.07. And the median was 1.05.


Precision BioSciences Beneish M-Score Historical Data

The historical data trend for Precision BioSciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precision BioSciences Beneish M-Score Chart

Precision BioSciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial -2.07 4.59 1.05 0.23 6.55

Precision BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 -1.51 -4.09 6.73 6.55

Competitive Comparison of Precision BioSciences's Beneish M-Score

For the Biotechnology subindustry, Precision BioSciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precision BioSciences's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precision BioSciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Precision BioSciences's Beneish M-Score falls into.



Precision BioSciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Precision BioSciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 9.1553+0.528 * 1+0.404 * 0.52+0.892 * 1.9415+0.115 * 1.0942
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.486+4.679 * 0.169244-0.327 * 1.0371
=6.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $12.80 Mil.
Revenue was 7.038 + 13.12 + 19.789 + 8.78 = $48.73 Mil.
Gross Profit was 7.038 + 13.12 + 19.789 + 8.78 = $48.73 Mil.
Total Current Assets was $136.36 Mil.
Total Assets was $159.78 Mil.
Property, Plant and Equipment(Net PPE) was $14.60 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.26 Mil.
Selling, General, & Admin. Expense(SGA) was $39.09 Mil.
Total Current Liabilities was $49.99 Mil.
Long-Term Debt & Capital Lease Obligation was $7.72 Mil.
Net Income was -16.289 + -8.079 + -11.891 + -25.06 = $-61.32 Mil.
Non Operating Income was 0.208 + -1.041 + -1.297 + -2.117 = $-4.25 Mil.
Cash Flow from Operations was -8.423 + -23.093 + -21.134 + -31.464 = $-84.11 Mil.
Total Receivables was $0.72 Mil.
Revenue was 10.598 + 7.363 + 3.82 + 3.317 = $25.10 Mil.
Gross Profit was 10.598 + 7.363 + 3.82 + 3.317 = $25.10 Mil.
Total Current Assets was $199.11 Mil.
Total Assets was $238.17 Mil.
Property, Plant and Equipment(Net PPE) was $13.78 Mil.
Depreciation, Depletion and Amortization(DDA) was $9.00 Mil.
Selling, General, & Admin. Expense(SGA) was $41.42 Mil.
Total Current Liabilities was $59.66 Mil.
Long-Term Debt & Capital Lease Obligation was $23.28 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(12.798 / 48.727) / (0.72 / 25.098)
=0.262647 / 0.028688
=9.1553

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(25.098 / 25.098) / (48.727 / 48.727)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (136.359 + 14.601) / 159.781) / (1 - (199.105 + 13.779) / 238.169)
=0.055207 / 0.106164
=0.52

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=48.727 / 25.098
=1.9415

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9.004 / (9.004 + 13.779)) / (8.255 / (8.255 + 14.601))
=0.395207 / 0.361174
=1.0942

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(39.088 / 48.727) / (41.423 / 25.098)
=0.802184 / 1.65045
=0.486

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((7.723 + 49.987) / 159.781) / ((23.282 + 59.664) / 238.169)
=0.361182 / 0.348265
=1.0371

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-61.319 - -4.247 - -84.114) / 159.781
=0.169244

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Precision BioSciences has a M-score of 6.55 signals that the company is likely to be a manipulator.


Precision BioSciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Precision BioSciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Precision BioSciences (Precision BioSciences) Business Description

Traded in Other Exchanges
Address
302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Executives
J. Jefferson Smith 10 percent owner C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Alan List officer: Chief Medical Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Michael Amoroso director, officer: President and CEO 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Dario Scimeca officer: General Counsel C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
John Alexander Kelly officer: Interim CFO C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Pharma Ag Novartis 10 percent owner LICHTSTRASSE 35, CH-4002, BASEL V8
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Derek Jantz director, 10 percent owner, officer: Chief Scientific Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Melinda Brown director 10 HUDSON YARDS, NEW YORK NY 10001
Shari Lisa Pire director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Samuel C. Wadsworth director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David S. Thomson officer: Chief Development Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Stanley Frankel director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Matthew R. Kane director, 10 percent owner, officer: President and CEO C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Shane Barton officer: VP & Corporate Controller C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701

Precision BioSciences (Precision BioSciences) Headlines